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Background: Several studies using acupuncture to treat essential hypertension have been carried out. However,
whether acupuncture is efficacious for hypertension is still controversial. Therefore, this trial aims to evaluate the
efficacy and safety of acupuncture for patients with mild hypertension.
Methods/Design: This is a large scale, open-label, multicenter, randomized controlled clinical trial with four parallel
arms. We will recruit 428 hypertensive patients with systolic blood pressure (SBP) between 140 and 159 mmHg,
diastolic blood pressure (DBP) between 90 and 99 mmHg. The participants will be randomly assigned to four
different groups (three acupuncture groups and one waiting list group) (1).The affected meridian acupuncture
group (n = 107) is treated with acupoints on the affected meridians (2).The non-affected meridian acupuncture
group (n = 107) is treated with acupoints on the non-affected meridians (3).The invasive sham acupuncture group
(n = 107) is provided with sham acupoints treatment (4).The waiting-list group (n = 107) is not offered any
intervention until they complete the trial. Each patient allocated to acupuncture groups will receive 18 sessions of
acupuncture treatment over 6 weeks. This trial will be conducted in 11 hospitals in China. The primary endpoint is
the change in average 24-hSBP before and 6 weeks after randomization. The secondary endpoints are average SBP
and average DBP during the daytime and night-time, and 36-Item Short Form Survey (SF-36), and so on.
Discussion: This is the first large scale, multicenter, randomized, sham controlled trial of acupuncture for essential
hypertension in China. It may clarify the efficacy of acupuncture as a treatment for mild hypertension.
Trials registration: Clinicaltrials.gov Identifier: NCT01701726.
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ProtocolBackground
Essential hypertension continues to be an important
public-health challenge worldwide [1]. Hypertension is an
independent risk factor for premature death, heart disease,
stroke, peripheral vascular disease, and renal failure.
Hypertension affects 29.3% of the adult population in the
United States [2]. In 2009,the direct and indirect costs
for hypertension in the United States are projected to be
approximately $73.4 billion [3]. In the fourth National* Correspondence: acuresearch@126.com
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reproduction in any medium, provided the orNutrition and Health Survey in 2002, the prevalence of
hypertension among Chinese population was 18.8% [4], af-
fecting approximately 200 million individuals in China,
while mild hypertension accounts for >60% [5]. Further-
more, the number of hypertensive patients is still in-
creasing [6]. It is also reported that in China, the direct
medical costs for hypertensive patientsaged 35 to 75
years are￥20.2 billion [7].
Pharmacological treatment remains the chief treat-
ment option for mild hypertension. However, a recent
Cochrane review found that there is no proved benefit
in antihypertensive drugs treatment for patients with
mild hypertension. In addition, owing to adverse effectshis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment [8]. Non-pharmacological interventions includ-
ing acupuncture prevail as a treatment option for hyper-
tensive patients [9]. In China, acupuncture has been used
to treat disease for >2,500 years, and it is also widely used
all around the world. Nowadays, acupuncture is used to
treat cardiovascular disease (such as angina pectoris [10],
hypertension [11]). Several randomized controlled trials of
acupuncture to treat hypertension had been conducted,
but the results were not consistent. Therefore, we de-
signed a multicenter randomized controlled trial to con-
firm whether acupuncture is efficacious and safe for
hypertension.
In this trial, we first intend to investigate the efficacy of
acupuncture to lower the blood pressure comparing
the waiting-list control and invasive sham acupuncture
groups. Second, we attempt to determine whether there is
a difference between acupoints on the affected meridians
according to meridian syndrome differentiation and the
acupoints on the non-affected meridians. This clinical trial
is financed by the national basic research program
(973program) in China, and is registered with an identifier
(NCT01701726) by clinicaltrials.gov in the USA.
Methods/Design
Design
This trial is an open-label multicenter randomized con-
trolled trial with four parallel arms. We compare the af-
fected meridians with non-affected meridians, sham
acupuncture and waiting-list groups as well. The trial is
performed in the following Hospitals: First Affiliated
Hospital of Chengdu University of Traditional Chinese
Medicine; Third Affiliated Hospital of Chengdu University
of Traditional Chinese Medicine (TCM); Affiliated Hospital
of Ningxia Medicine University; First Affiliated Hospital of
Hunan University of TCM; Second Affiliated Hospital of
Hunan University of TCM; Affiliated Hospital of Hunan
University of TCM - Hengyang Hospital; Chenzhou No.1
People’s Hospital; First Affiliated Hospital of Guiyang
College of TCM; Second Affiliated Hospital of Guiyang
College of TCM; Yunnan Provincial Hospital of TCM; and
Second Affiliated Hospital of Shanxi College of TCM.
The whole study period is 13 weeks,with a 1-week run-in
period, 6-week treatment phase, and 6-week follow-up
phase. After randomization, patients in acupuncture groups
will receive 18 sessions of treatment over a 6-week treat-
ment period. Participants in the waiting-list control group
will give an option to receive acupuncture treatment after
13 weeks study period. Outcome measurements will be
assessed at day 0, 6 weeks, 9 weeks, and 12 weeks after
randomization. All patients will be informed that they may
be randomly allocated to affected meridian acupuncture
group, non-affected acupuncture group, invasive sham acu-
puncture group, or waiting-list group (Figure 1, Table 1).This trial will be conducted according to the principles of
the Declaration of Helsinki (version Edinburgh 2000). The
trial protocol has been approved by the regional ethical re-
view committee of traditional Chinese medicine in Sichuan
Province on April 2012. We will require all patients to sign
the written informed consent, and they will be given
enough time to decide whether they will take part in this
trial. This trial started in September 2012, and will be com-
pleted in December 2017.
Randomization
Randomization is conducted by the third party (the
Brightech Magnsoft Data Services Company) using text
messages or a website. If the randomization succeeds,
the investigators will receive an email confirmation. The
randomization sequence (blocked, stratified for centers) is
generated through the randomization module of the syn-
thesized management platform of the Brightech Magnsoft
Data Services Company (block length is unknown to cen-
ters). This procedure ensures each eligible patient having
an equal probability of being assigned to four different
groups, which will not be influenced by the researchers.
Participants
Patients who meet the inclusion criteria will be included
in this study. The criteria are as follows: (1) men or
women aged between 40 and 75 years,; (2) participants
meet the diagnostic criteria of mild hypertension accord-
ing to JNC-7 [12] and 2010 Chinese guidelines for the
management of hypertension [5](diagnosed as mild hyper-
tension systolic blood pressure (SBP) 140–159 and/or
diastolic blood pressure (DBP) 90–99 ,according to WHO/
ISH criteria stage I); (3) patients who are initially diag-
nosed as mild hypertension or have been diagnosed as
mild hypertension before, without taking any antihyper-
tensive drugs; (4) patients who are diagnosed as Jue-yin
syndrome (yin-deficiency accompany with hyperactivity of
yang) or Yang-ming syndrome (obstruction of phlegm
and dampness) according to meridian syndrome differenti-
ation; (5) patients who are willing to comply with our
study protocol; (6) participants agree to sign informed
consent form.
The exclusion criteria are as follows: (1) patients who
have been diagnosed with secondary hypertension [13]
or malignant hypertension (for example, Cushing’s syn-
drome, coarctation of the aorta, pheochromocytoma, renal
parenchymal disease, primary aldosteronism, renovascular
hypertension, obstructive sleep apnea, drug-induced hyper-
tension, and so on); (2) patients accompanied with other se-
vere medical conditions (for example, endocrine disorders,
cardiovascular disease, digestive disease, hepatic dysfunc-
tion, cerebral vascular disease, renal disease, hematologic
disease,and so on); (3) patients with a chronic disease (for
example, epilepsy, severe depression, or anxiety (SAS ≥70,
Randomization






























Figure 1 Trial flow chart.
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any infection), pregnant women or women in lactation or
women of childbearing potential planning to conceive in
the next 6 months; (4) patients who currently participate in
another clinical trial; (5) patients who had been treated with
acupuncture during the previous 3 months. If one of the
criteria mentioned above is matched, the participant will be
excluded.
During the whole study period, participants will not be
hospitalized, taking into account: (1) we only recruit pa-
tients with mild essential hypertension who went off
hypertensive drugs and without complications; (2) we
could observe the blood pressure of participants under
regular activities; (3) patients with mild essential hyper-
tension are not appropriate to recruit for inpatient
treatment.
Recruitment strategies
We will apply two strategies to recruit participants with
mild hypertension. First, we recruit participants from out-
patient clinics of the participated hospitals. Second, we
employ three kinds of advertisements to attract patients to
join our study. We will distribute printed recruitment
posters in the participated hospitals and the communities
nearby. Meanwhile we will publish advertisement in localnewspaper and broadcast television advertisements on the
local channel.
Intervention
Rationale for selection of acupoints According to TCM
theory, hypertension pertains to the coverage of vertigo
and headache. Based on previous survey and expert con-
sultation, Jue-yin syndrome (yin deficiency with yang
hyperactivity) and Yang-ming syndrome (the obstruction
of phlegm and dampness) are the most common syn-
dromes in mild hypertension. Therefore, in accordance
with meridian syndrome differentiation, we select acu-
points on the Yang-ming, Jue-yin, and Shao-yin merid-
ians. Hence, it is reasonable that the acupoints on the
affected meridians would be most effective at treating
mild hypertensive patients. Meanwhile we also choose
acupoints on the non-affected meridians (Gallbladder,
San-jiao, and Spleen meridians) which were reported to
be useful to decrease blood pressure according to our
previous literature research.
In our trial, there are four groups: (1) affected merid-
ian group;(2) non-affected meridian group;(3) sham acu-
puncture group;and (4) waiting-list group (Table 2).
Apart from the waiting-list group, the other patients
Table 1 Time to visit and data collection
−1 week 0 week 3 weeks 6 weeks 3 weeks after treatment 6 weeks after treatment







Affected meridian acupuncture group (n = 107) 18 sessions of acupuncture at
acupoints
Non-affected meridian acupuncture group (n = 107)
Comparisons
Incasive sham acupuncture group (n = 107) 18 sessions of acupuncture at
non-acupoints
Waiting-list group (n = 107) 18 sessions of treatment at
the end of the trial
Outcomes
24-h blood pressure x x x x
Expectation of acupuncture x
SF- 36 x x
Response to treatment x
Participants safety
Laboratory test x
Adverse events x x x x x
SAS, Self-Rating Anxiety Scale; SDS, Self-Rating Depression Scale; SF-36, MOS item Short Form health survey.
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AMA,Participants in the affected meridian group
(Figure 2) are treated according to two syndromes
(Jue-yin syndrome and Yang-ming syndrome).
Jue-yin syndrome: taichong (LR3), renying (ST9), taixi
(KI3), and neiguan (PC6) are punctured with filiform
needles bilaterally. Taichong (LR3) is punctured per-
pendicularly 0.5-1.0 cun. Renying (ST9) is punctured
perpendicularly 0.3-0.8 cun, paying attention to
avoiding the carotid artery. Taixi (KI3) is puncturede 2 Details of acupuncture protocol
Jue-yin syndrome Taichong (LR3), renying(ST9), taixi(KI3), neiguan(PC6
Yan-ming syndrome Taichong (LR3), renying(ST9), zusanli(ST36), quchi(L
Fengchi(GB20), waiguan(SJ5), yinlingquan(SP9), xue
1. The edge of the tibia (1–2 cm lateral and horizo
2. Halfway between the tip of the elbow and the a
3. On the ulnar side of the arm, halfway between th
4. 2 cm superior to futu(LI18)
Affected meridian acupuncture group; ISA, Invasive sham acupuncture group; NMA,perpendicularly 0.5-1.5 cun. Neiguan (PC6) is
punctured perpendicularly 0.5-1.0 cun. Yang-ming
syndrome: taichong (LR3), renying (ST9), zusanli
(ST36), and quchi (LI11) are punctured with filiform
needles bilaterally. Taichong (LR3) is punctured
perpendicularly 0.5-1.0 cun. Renying (ST9) is punc-
tured perpendicularly 0.3-0.8 cun, paying attention
to avoiding the carotid artery. Zusanli (ST36) is
punctured perpendicularly 1.0-2.0 cun. Quchi (LI11)
is punctured perpendicularly 1.0-1.5 cun.
After insertion, all the acupoints will be manually
stimulated by lifting and thrusting associated with
twirling and rotating the needle, to elicit ‘de-qi’.)
I11)
hai(SP10)
ntal to the zusanli (ST36))
xilla
e epicondylus medialis of the humerus and the ulnar side of the wrist
Non-affected meridian acupuncture group.
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identified by the practitioner according to the
diagnostic characteristic variables of TCM (Table 3).
2. Non-affected meridian acupuncture (NMA)
Fengchi (GB20), waiguan(SJ5), yinlingquan(SP9), and
xuehai (SP10) are punctured by filiform needles
bilaterally (Figure 3). Fengchi (GB20) is punctured
obliquely 0.8-1.2cun, with the tip of the needle
pointing to the apex of nose. Waiguan (SJ5) is
punctured perpendicularly 0.5-1.0 cun. Yinlingquan
(SP9) is punctured perpendicularly 1.0-2.0 cun. Xuehai
(SP10) is punctured perpendicularly 1.0-1.5cun. All the
acupoint locations are in accordance with the WHO
Guideline for Acupuncture Point Locations [14].
After insertion, all the acupoints will be manually
stimulated by lifting and thrusting associated with
twirling and rotating the needle, to search for ‘de-qi’.
3. Invasive sham acupuncture (ISA)
Sham acupoints (Figure 4):
(1)The edge of the tibia (1–2 cm lateral and
horizontal to the zusanli (ST36))
(2)Halfway between the tip of the elbow and the axilla
(3)On the ulnar side of the arm, halfway between
the epicondylus medialis of the humerus and the
ulnar side of the wrist
(4)2 cm superior to fu tu (LI18)
We use pre-validated sham acupoints [15]. After the
insertion, we will not use any manipulationand ‘de-qi’
sensation is not needed.ble 3 Diagnostic characteristic variables of TCM
Yin deficiency with yang hyperactivity
lse Wiry, thin,fast




Vertigo, headache, malar flush, both knee and loin feel sore an
dysphora in chest, palms, and soles, irritable, dry mouth, dry e
palpitation, insomnia, poor memory
econdary
ymptoms
Concentrated dark urine, dry stools, blurred vision, numbness
limbs, tinnitus4. Waiting-list (WL)
Participants in the WL group will not be treated
throughout 13-week observation period. And they
will be required to maintain their current lifestyle,
including diet and exercise. At the end of trial, if the
participant would like to be treated with acupunc-
ture, we will offer acupuncture treatment three
times weekly for 6 weeks.
During the whole study period, all the participants are
not allowed to take any medical treatment for lowering
blood pressure; drugs, herbs, and physical therapy are
forbidden. If the participants suffer from other diseases
and need to be treated with drugs,they have to record
the drugs they take, and measure their blood pressure
after drugs, all of which will be recorded in the case re-
port forms.
In each session, acupuncture is applied bilaterally. After
insertion, apart from the acupoints around the neck (ST9,
GB20, non-acupoints4), six auxiliary needles will be punc-
tured at 2 mm lateral to each acupoint or non-acupoint.
As to the auxiliary needle, we will not do any manipula-
tion. We use transcutaneous electric acupoints stimulation
(HANS; Han’s acupoints nerve stimulator, HANS-200,
Nanjing, China) to stimulate the acupoints and non-
acupoints. Except for the acupoints around the neck (ST9,
GB20, non-acupoints 4), the other acupoints or non-
acupoints and their auxiliary needles are connected with





Heavy head and or body, muddled thinking,
overweight, vertigo, palpitation, poor appetite, nausea,
stuffy feeling in the chest and/or epigastrum, heavy
frontal headache, insomnia
and tremors of Tinnitus, numbness in the limbs, loose stools
Figure 3 Locations of acupoints: non-affected meridian acupuncture group (NMA).
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strated that 30 min of low-frequency electro-acupuncture
activates opioid receptors and provides a therapeutic effect
on hypertension [16,17].
The treatment will be performed after sterilizing the
skin with 75% alcohol on the areas where the needles
will be inserted, and with the patient lying in the supine
position. We use two types of Hwato disposable steel
needles (Suzhou Hua Tuo Medical Instuments, Suzhou,
China): length 25–40 mm, diameter 0.25 mm; and
length 13 mm, diameter 0.18 mm. All the groups but
the patients in waiting-list group are asked to retain the
needles for 30 min.
Apart from waiting-list group, the patients from the
other groups will receive 18 sessions of acupuncture
treatment over 6 weeks, three times per week. During
the whole observation period, no patients are allowed to
take antihypertensive drugs.Figure 4 Locations of non-acupoints: invasive sham acupuncture groOutcome measurement
Primary endpoint The primary outcome measurement
in this study is the change in average 24-hSBP and DBP
before randomization and 6 weeks after randomization.
Ambulatory mean blood pressure (ABPM) is superior
to clinic BP in the prediction of cardiovascular morbid-
ity and mortality [18,19]. Because ABPM exerts a differ-
ent predictive effect on the cardiac and cerebrovascular
complications [20] we selected ABPM as our primary
endpoint.
Secondary outcome measures Ambulatory pulse pres-
sure (APP) [21] is a well-established marker of cardio-
vascular risk. We choose APP as one of the secondary
endpoints to evaluate the effect of acupuncture for
hypertension. There is a prospective study [22] that shows
that both high ABPM values and abnormal daytime/night-
time BP profiles are associated with later occurrence ofup (ISA).
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ently of casual BP values and other cardiovascular risk fac-
tors. It is therefore necessary to observe the daytime/
night-time BP of hypertensive patients.
Changes in patients’ health-related quality of life, ac-
cording to the SF-36 (Medical Outcomes Study 36-Item
Short Form) questionnaire Chinese version is another
secondary outcome measure [23]. The validity and reli-
ability of this scale have proven in previous studies
[24,25]. The scale contains eight dimensions (physical
function, role physical, bodily pain, general health, vital-
ity, social function, role emotional, mental health) and
two summary components (physical and mental), mea-
sured on a scale of 0 to 100. Lower scores indicate a
poorer quality of life. SF-36 investigates at 0 day and 6
weeks after randomization.
Response to the treatment will be measured at the end
of treatment, using a five-point Likert self-administered
scale:‘Compared with pre-treatment, to what extend did
you think your hypertensive symptoms change?’1, absence
of all symptoms; 2, significantly improved; 3, moderately
improved; 4, not changed; 5, deteriorated. ‘After treatment,
how do you evaluate the effect of acupuncture for hyper-
tension?’ 1, no effect(0%); 2, a little effect(25%); 3, moder-
ate effect(50%); 4, a significant effect (75%); 5, complete
response(100%). The patients fill in this questionnaire at
the end of the treatment.
Expectation of the treatment will be measured by a
self-administered questionnaire. With seven items as fol-
lows: (1) In the coming year, how will you think your
disease will be relieved? (significantly(≥75%); moderately
(approximately 50% to 75%); a little(approximately 25%
to 50%); no change(0% to 25%)); (2) How effective do
you think acupuncture is for hypertension? (significant
(≥75%); moderate(approximately 50% to 75%); a little
(approximately 25% to 50%); no change(approximately 0%
to 25%)); (3) Which treatment options do you prefer to
take as your treatment for hypertension? (acupuncture
and moxibustion; herbs; Western medicine; others); (4)
How familiar are you with acupuncture and moxibus-
tion? (very familiar; so-so; a little; not at all); (5) By what
means did you get to know about acupuncture and
moxibustion? (friends and relatives; media reports; med-
ical work; others); (6) How did acupuncture and moxi-
bustion work in your memory? (excellent; good; so-so;
not at all); (7) During the treatment, are you afraid of
the pain or uncomfortable sensation caused by acupunc-
ture and moxibustion? (very much; a little; never think
about it; feel comfortable). The subjects will mark the
best answer for each of the questions. The assessment
will be performed at day 0 after randomization.
Before randomization, a special pattern identification
questionnaire was developed to differentiate which syn-
drome the subjects pertaining to.Blood pressure measurement
Ambulatory blood pressure measurements are performed
with an oscillometric device (A&D Co.Ltd., Japan TM-
2430). During a 24-h monitoring period, the device takes
76 measurements. Daytime is defined as 08:00–22:00. The
measurement during the daytime will be taken every 15
min. Night-time is defined as 22:00–08:00. The measure-
ment during the night-time will be taken every 30 min.
The 24-h ambulatory blood pressure monitoring measures
at baseline, 6 weeks, 9 weeks, and 12 weeks after ran-
domization. Clinical blood pressure measurements will be
taken before and after each acupuncture session with
Automatic Upper Arm Blood Pressure Monitor (Omron
HEM 7200, Liaoning, China).
Participant safety
Before randomization, all participants will undergo rou-
tine tests of blood, urine, stool sample, electrocardio-
gram examination, Doppler echocardiography, carotid
ultrasonography, as well as blood biochemical tests
(AST, ALT, BUN, Scr, fasting glucose, triglyceride, HDL
cholesterol, LDL cholesterol, albumin/creatinine.). These
tests will help identify and exclude participants with ser-
ious illnesses of the heart, liver, and kidneys, or other se-
vere diseases.
Adverse events are defined as any unexpected or un-
comfortable signs, symptoms, or diseases, regardless of
the intervention. These adverse events include bleeding,
hematoma, fainting, serious pain, and local infection. If
any adverse events happen during the entire observation
period, all the details should be documented in the case
report form.
We have designed a case reported form containing a
variety of information, and this will be completed by the
corresponding researchers at each center. At each center,
the obtained information will be recorded on an elec-
tronic database, for subsequent statistical analysis. Dur-
ing the observation period, if there are any drop-outs or
withdrawals, the investigator must find out their reasons
and record them in the case report form. The patients’
compliance during the 6 weeks of treatment and 6 weeks
of follow-up will also be documented.
Sample size calculation and statistical analysis
According to the previous literature [26], the average
24-hSBP of hypertensive patients rose 1.6 mmHg after
being treated by sham acupuncture, while the average
24-hSBP of hypertensive patients lowered 5.4 mmHg
after being treated with verum acupuncture. Therefore,
the adjusted mean difference between the two groups
was 7 mmHg. In this study, we anticipated an 12 mmHg
improvement by affected meridian acupuncture; 10
mmHg by non-affected meridian acupuncture; 3 mmHg
by sham acupuncture; and 0 mmHg in the waiting-list
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this using 90% power at a 5% significance level with
G*Power (version 3.1.2, Franz Faul, Universität Kiel,
Germany), and the result showed an estimated 93 pa-
tients per group. Considering a drop-out rate of 15%, we
plan to enroll 107 patients per group, 428 patients in
total for the four different groups.
Statistical analysis protocol was designed by the
Brightech-Magnsoft Data Services Company and princi-
pal investigators. Analysis of all data in this trial will be
performed by the Brightech-Magnsoft Data Services
Company. The data will be analyzed with SAS 9.1 and
SPSS13.0 software packages. All analyses will be on the
basis of the intention-to-treat (ITT) population and per-
protocol (PP) population. The result of the ITT analysis
will be compared with that of the PP analysis to deter-
mine whether the results are consistent. Missing data
will be filled by Last Observation Carry Forward rules.
Demographic characteristics and other baseline values
will be described using descriptive statistics for each
group. For the primary outcome, we will run a compari-
son between pooled acupuncture groups and waiting list
control group to figure out whether acupuncture is more
effective for this condition. We will then run another
comparison between the pooled acupuncture groups and
sham acupuncture group to find out whether acupunc-
ture is more efficacious. Finally, a comparison between
acupuncture groups will be run to see if selecting points
along meridians was a better treatment option. The
above analysis will be performed using the ANCOVA
model. Multiple comparisons will be adjusted according
to the Bonferroni correction method.
The repeated measures analysis will be used in the dif-
ferent time point assessments for the secondary out-
comes. The Kruskal-Wallis test will be employed in the
analysis of skewed distribution data. There is a desig-
nated acupuncturist in each center to all the acupuncture
treatment, which probably introduces clustering effect in
this trial. Therefore, we calculated the intra-cluster correl-
ation coefficient from the results of this trial and report
the coefficient.
Discussion
Acupoints are the regions where qi and blood from the
viscera and meridians effuse and infuse beneath the body
surface; the meridians and collaterals internally pertain
to viscera and externally connect with the extremities.
Therefore, stimulating the acupoints on the affected me-
ridians can produce specific effects on regulating the
corresponding organs, and the specificity of acupoint ef-
fect is the important basis for this regulation effect
[27,28]. However, the specificity of acupoint effect on
the affected meridians, continues to be a conflicting the-
oratical issue in acupuncture field [29,30]. In recentyears, much research on acupoint specificity has been
launched, but the resultsare still inconclusive. There is a
small sample study of 41 randomized hypertensive pa-
tients into two groups (one gave verum acupuncture,
and the other received non-penetrating sham acu-
puncture). After 17 treatment sessions, the verum acu-
puncture group showed a significant decrease in blood
pressure [31]. Similar results had been found in another
study, which discovered that unlike sham acupuncture,
after 6weeks of treatment with acupuncture according to
TCM, the verum acupuncture significantly decreased
mean 24-h ambulatory blood pressure [26]. On the other
hand, another study of a higher quality obtained negative
results on comparing active acupuncture with invasive
sham acupuncture. They founded that active acupunc-
ture provided no greater benefit than invasive sham acu-
puncture in reducing SBP or DBP [32].
Therefore, we launch this trial by means of multiple
comparisons of four different arms (affected meridian
acupuncture, non-affected meridian acupuncture, inva-
sive sham acupuncture, and waiting-list groups) to aim
to clarify this issue. First, we compare the efficacy of
acupoints on the affected meridian with the waiting-list
group who do not receive any intervention during the
whole observation period. Second, we compare this with
the invasive sham acupuncture group. We then compare
the acupoints on the non-affected meridians. We believe
that affected meridians based on syndrome differenti-
ation acupuncture are capable of lowering the elevated
blood pressure of hypertensive patients, of which effect
is better than non-affected meridian acupuncture, and
to a greater degree than the sham acupuncture and
waiting-list groups. It can enhance health-related quality
of life. Furthermore, as a treatment option for hyperten-
sion, it caused less adverse side effects. Through this
trial, we attempt to demonstrate the real effectiveness of
acupuncture for hypertension, and illustrate the specific
effect of acupoints on the affected meridian.
Design highlights: first, unlike previous trials, we only
include mild hypertensive patients without serious com-
plications as it is safe for all subjects to go off hyperten-
sive drugs and only be treated with acupuncture. We
also rule out the influence from hypertensive drugs.
Besides, by focusing on mild hypertension [33], we can
cut down the compounding effect from different sever-
ities of hypertension. Second, we use electro-stimulation
in the acupuncture groups aiming to ensure the stimula-
tions between groups and individualsare equal. Third, in
order to ensure the quality of this trial, we require that
all the participating acupuncturists have at least 5 years
of training and 5 years of practical experience. Before
the trial, they will take a training course which includes
the study protocol, methods for acupuncture treatment,
and operating demonstration for this trial. After the
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course to be qualified for this trial. Meanwhile, we will
designate special clinical monitors to check the progress
of the trial and audit the accuracy and validity of the ori-
ginal data at each participating hospital once a month.
Fourth, in our trial, a first ever large sample of patients
will be recruited, which will make the results more
powerful and convincing. Moreover, our design has a
good understanding of theory of TCM and acupuncture.
One important limitation that may be present in this
study is that it is an open-label trial. We design a
waiting-list group as a blank controlled group. It is im-
possible to execute a blinding method. In order to over-
come this problem, the acupuncturist and the outcome
assessors are different, with respect to making the out-
come assessment objectively. We also prevent the inves-
tigators and statisticians from randomization, to make
sure all of them are blind to allocation. Among the three
acupuncture groups, we conceal the patients from assig-
nation so the patients do not know which acupuncture
group they are allocated in.
This is a large scale, multicenter, randomized, con-
trolled trial, and utilizes high quality methodologies. It
may provide evidence for the effectiveness of acupunc-
ture as a treatment for mild hypertension and confirm
the existence of special effect of acupoints on affected
meridians based on meridian syndrome differentiation.
Trial status
The first participant was included on 30 September
2012, and this article was submitted on 30 June. To date,
184 participants have been recruited.
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